Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,137 shares of the biotechnology company’s stock after selling 2,275 shares during the period. Teacher Retirement System of Texas’ holdings in Sarepta Therapeutics were worth $1,477,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $30,000. Center for Financial Planning Inc. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth about $31,000. Steward Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Sarepta Therapeutics by 53.0% in the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 276 shares during the last quarter. Finally, Logan Capital Management Inc. purchased a new position in shares of Sarepta Therapeutics in the fourth quarter worth approximately $61,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 4.7%

SRPT stock opened at $18.17 on Friday. The business has a fifty day moving average of $30.98 and a 200-day moving average of $71.91. The company has a market cap of $1.79 billion, a P/E ratio of -6.75 and a beta of 0.45. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics, Inc. has a twelve month low of $16.88 and a twelve month high of $154.13.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the firm posted $0.73 earnings per share. The firm’s revenue was up 80.2% on a year-over-year basis. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SRPT. Scotiabank raised shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 target price on the stock in a research report on Friday, June 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Sarepta Therapeutics in a research note on Monday, June 16th. William Blair restated a “market perform” rating on shares of Sarepta Therapeutics in a research note on Friday, June 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 price objective (down previously from $113.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Finally, Mizuho decreased their price target on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus target price of $58.54.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.